Key result
Calcium sensitizers such as levosimendan may offer long-lasting results for the treatment of heart failure compared to classic inotropic drugs.
Why the study?
Does levosimendan offer long-lasting haemodynamic enhancement compared to classic inotropic drugs in patients with heart failure?
Population
Patients with heart failure and low cardiac output requiring acute cardiac care
Comparison
Levosimendan (calcium sensitizer) vs Classic inotropic drugs
Design
Review
Authors
Loading...
May support levosimendan preference in acute HF for sustained effects; leaves open confirmation in randomized trials.
Does levosimendan offer long-lasting haemodynamic enhancement compared to classic inotropic drugs in patients with heart failure?
Levosimendan, a calcium sensitizer, may provide a long-lasting hemodynamic benefit in acute heart failure compared to traditional inotropes that are associated with poor prognosis.
Mohammad Asif (2014) conducted a review in Heart failure. Levosimendan (Calcium sensitizers) vs. Classic inotropic drugs (beta-adrenergic agonists, phosphodiesterase inhibitors) was evaluated. Calcium sensitizers such as levosimendan may offer long-lasting results for the treatment of heart failure compared to classic inotropic drugs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: